Institution

Hôpital Lyon Sud

Pierre-Bénite, FranceWebsite

Also known as: Centre Hospitalier Lyon Sud · CHLS

173running trials
125closed trials
17,713publications (OpenAlex)

Running trials

Not yet recruiting
A Study of Eloralintide (LY3841136) in Participants With Obesity or Overweight, Type 2 Diabetes, and Increased Cardiovascular Risk
NCT07900633· Phase 3· Eli Lilly and Company· Source
Not yet recruiting
Investigation of Type I Interferon Excess in Patients With Systemic Autoimmune Diseases and Genetic Type I Interferonopathies
NCT07837986· Hospices Civils de Lyon· Source
Not yet recruiting
Functional Outcomes of the Miami Pouch Continent Cutaneous Urinary Diversion: A Quality of Life Study
NCT07931924· Hospices Civils de Lyon· Source
Not yet recruiting
CRYO-TOUCH: Cryoablation of the Primary Breast Tumor in Metastatic Breast Cancer
NCT07676344· Hospices Civils de Lyon· Source
Not yet recruiting
Prospective Evaluation of Subcutaneous Administration of Daratumumab by the FreedomEDGE® Infusion System
NCT07721350· Hospices Civils de Lyon· Source
Not yet recruiting
Study Evaluating the Efficacy and Safety of the Addition of Ivosidenib to Oral Azacitidine (Onureg®) in Patients Over 55 With Acute Myeloid Leukemia (AML) and IDH1 Mutation, in Complete Remission After Intensive Chemotherapy.
NCT07463768· Phase 2· French Innovative Leukemia Organisation· Source
Recruiting
Probiotic Intervention for Digestive Health in Obese Patients Initiating GLP-RA Treatment
NCT07213323· Hospices Civils de Lyon· Source
Not yet recruiting
SENSILINS: Impact of Cephalic Phase Insulin Release Induced by an Environmental Food Odor Stimulus on Glucose Homeostasis According to Insulin Sensitivity Level
NCT07638111· Hospices Civils de Lyon· Source
Recruiting
Implementing Low-dose ct Lung Cancer Screening in France.
NCT07513818· Assistance Publique - Hôpitaux de Paris· Source
Recruiting
MATRIX-IPC 2022-029 A phase I/II study evaluating Tuvusertib (M1774), an ATR Inhibitor, in combination with fulvestrant in hormone receptors-positive and HER2-negative, advanced breast cancers, resistant to CDK4/6 inhibitor plus aromatase inhibitor-based endocrine treatment and with homologous recombination deficiency, oncogenic driver activation and/or other molecular alterations associated with replication stress (RS)
NCT05986071· Phase 1/2· Institut Paoli-Calmettes· Source
Recruiting
LY4268989 in Adults With Moderately to Severely Active Ulcerative Colitis
NCT07415044· Phase 2· Eli Lilly and Company· Source
Not yet recruiting
ActiTENS Mini (Transcutaneous Electrical Stimulation) in Women With Chronic Pain From Pelvic Endometriosis
NCT07317037· Assistance Publique - Hôpitaux de Paris· Source
Not yet recruiting
Food-related Quality of Life in Patients With Cancer
NCT07437326· Hospices Civils de Lyon· Source
Recruiting
Feasibility Trial of Extracorporeal Iron Purification in Patients With Myelodysplastic Syndrome or Myelofibrosis
NCT06781099· Hospices Civils de Lyon· Source
Recruiting
A Phase 1/2a Study of UCART20x22 in B-Cell Non-Hodgkin Lymphoma [NatHaLi-01]
NCT05607420· Phase 1/2· Cellectis· Source
Recruiting
Withdrawal of Dupilumab in Severe Asthma
NCT06818019· Phase 4· University Hospital, Toulouse· Source
Recruiting
A Study of Vepugratinib (LY3866288) in Participants With Cancer in the Urinary Tract
NCT07218380· Phase 3· Eli Lilly and Company· Source
Not yet recruiting
Association Between Composition of the Gut Microbiota and Nutritional Status in Digestive Oncology
NCT07260617· Hospices Civils de Lyon· Source
Recruiting
A Study of ZL-1310 Versus Investigator's Choice of Therapy in Participants With Relapsed Small Cell Lung Cancer (DLLEVATE)
NCT07218146· Phase 3· Zai Lab (Shanghai) Co., Ltd.· Source
Recruiting
Impact of a Pro-diversity Gut Microbiota Diet After a Bariatric Surgery on Gut Microbiota, Eating Behaviour and Sensory Function
NCT07268508· Hospices Civils de Lyon· Source
Recruiting
A Master Protocol of Multiple Agents in Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease (SYNERGY-Outcomes)
NCT07165028· Phase 3· Eli Lilly and Company· Source
Recruiting
Adjuvant FOLFIRI Based-chemotherapy After Resection of CLM Responding to Preoperative FOLFIRI
NCT06501482· Phase 3· Assistance Publique - Hôpitaux de Paris· Source
Recruiting
Using an Intervention Adapted to the Health Literacy Level to Improve Adherence to Medical Recommendations
NCT03951467· Hospices Civils de Lyon· Source
Recruiting
Mobile Lung Cancer Screening
NCT07015151· Hospices Civils de Lyon· Source
Active, not recruiting
A Study to Evaluate Axatilimab Versus Best Available Therapy in Participants With Chronic Graft Versus Host Disease After at Least 2 Prior Lines of Systemic Therapy
NCT06821542· Phase 3· Incyte Corporation· Source
Recruiting
A Study to Assess Adverse Events and Change in Disease Activity in Participants With Platinum-Resistant Advanced High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers With High Folate Receptor-Alpha Expression Treated With Intravenously (IV) Infused Mirvetuximab Soravtansine
NCT06682988· Phase 2· AbbVie· Source
Recruiting
A Study of Duvelisib Versus Gemcitabine or Bendamustine in Participants With Relapsed/Refractory Nodal T Cell Lymphoma With T Follicular Helper (TFH) Phenotype
NCT06522737· Phase 3· SecuraBio· Source
Recruiting
Initial Standardized Global Review in Axial Spondyloarthritis
NCT07141017· Association de Recherche Clinique en Rhumatologie· Source
Recruiting
Blood Clearance Kinetics of the Nucleosome and CTCF in Peritoneal Metastasis Colorectal Cancer.
NCT06929013· Hospices Civils de Lyon· Source
Recruiting
Study of the Link Between MASH ( Metabolic Dysfunction-Associated Steatohepatitis) and MAMs (Mitochondria-Associated Membranes ) Alteration in Patients Undergoing Bariatric Surgery - MAMBA
NCT06868992· Hospices Civils de Lyon· Source
Recruiting
Study Evaluating the Efficacy and Safety of Darolutamide and Stereotactic Dose Escalated Radiotherapy in Patients With Localized Prostate Cancer and High-risk Features of Relapse
NCT06625970· Phase 3· UNICANCER· Source
Recruiting
Evaluation of Sleep Changes in Inflammatory Bowel Diseases (IBD) Patients.
NCT05835973· Hospices Civils de Lyon· Source
Recruiting
KONO-S Anastomosis Compared to Conventional Ileocolonic Anastomosis to Reduce Recurrence in Crohn's Disease
NCT05974358· Centre Hospitalier Universitaire de Besancon· Source
Recruiting
A Study to Learn More About How Well Treatment With Sevabertinib (BAY 2927088) Tablets Works and How Safe it is in Participants Who Have a Solid Tumor With Mutations of the Human Epidermal Growth Factor Receptor 2 (HER2)
NCT06760819· Phase 2· Bayer· Source
Recruiting
Trial of Therapeutic Cancer Vaccine OSE2101 in Patients With Non-Small Cell Lung Cancer and Secondary Resistance to Immune Checkpoint Inhibitor
NCT06472245· Phase 3· OSE Immunotherapeutics· Source
Recruiting
Treatment With Darolutamide +/- Radiation Therapy for Patients With a Castration Resistant Cancer and Metastases Detected by Functional Imaging
NCT06276465· Phase 3· UNICANCER· Source
Recruiting
Study on the Relative Dose Intensity of PARP Inhibitors in Real-life on a Population of Patients Over 70 Years With Advanced Ovarian Cancer
NCT06572735· Hospices Civils de Lyon· Source
Recruiting
Physical Activity Profile and Sedentary Behaviour in Adults With Cystic Fibrosis
NCT06507956· Hospices Civils de Lyon· Source
Recruiting
Blood Viscosity in Polycythemia Patients
NCT06421025· Hospices Civils de Lyon· Source
Not yet recruiting
Efficacy and Tolerance of Abacavir/Lamivudine Treatment in Patients With Systemic Lupus Erythematosus
NCT06356740· Phase 2· Hospices Civils de Lyon· Source
Recruiting
LUNAR-2: TTFields With Pembrolizumab + Platinum-based Chemotherapy for Metastatic NSCLC
NCT06216301· Phase 3· NovoCure GmbH· Source
Active, not recruiting
Treatment of microstellite stable metastatic colorectal cancer presenting high immune infiltrate with chemotherapy (XELOX or FOLFOX Bevacizumab) and immunotherapy ( Pembrolizumab)
NCT04262687· Phase 2· Fondation Franc.Cancerologie Digestive· Source
Recruiting
A Phase 2 study to evaluate the efficacy and safety of selinexor monotherapy in subjects with JAK inhibitor-naïve myelofibrosis and moderate thrombocytopenia.
2024-511309-47-00· Phase 2· Karyopharm Therapeutics Inc.· Source
Active, not recruiting
Minimal Residual Disease-based Strategy with T-Cell Redirector After Treatment with Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone (D-VRd) in Newly Diagnosed Multiple Myeloma: A Phase 2 (IFM 2022-01).
2023-508310-41-00· Phase 2· Centre Hospitalier Universitaire De Nantes· Source
Recruiting
National Registry of Surgical Treatment and Percutaneous Cryoablation of Parietal Endometriosis
NCT06356831· Centre Hospitalier Intercommunal Creteil· Source
Active, not recruiting
MorningLyte: Evaluation of the benefits of the combination of mosunetuzumab plus lenalidomide versus a treatment with anti-CD20 monoclonal antibody plus chemotherapy in subjects with previously untreated FLIPI 2-5 follicular lymphoma
2023-505436-35-00· Phase 3· Lysarc· Source
Recruiting
A Study of Selinexor Monotherapy in Subjects With JAK Inhibitor-naïve Myelofibrosis and Moderate Thrombocytopenia
NCT05980806· Phase 2· Karyopharm Therapeutics Inc· Source
Recruiting
Phase 1, Safety and Tolerability Study of XmAb541 in Advanced Solid Tumors
NCT06276491· Phase 1· Xencor, Inc.· Source
Recruiting
A Clinical Study of MK-4208/TERN-701 in Participants With Chronic Myeloid Leukemia (CML) (MK-4208-003/Tern701-1012/CARDINAL)
NCT06163430· Phase 1/2· Terns, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)· Source
Recruiting
FILOCLL015 - GLORIFY - A phase 2 study evaluating the bispecific CD3xCD20 antibody GLOfitamab in combination with rituximab or obinutuzumab plus cyclophosphamide, doxorubicin, vincristine and prednisone (CHOP) in patients with RIchter syndrome as Frontline therapY
2022-501554-11-00· Phase 2· French Innovative Leukemia Organization· Source

Showing 50 of 173.

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

Lung cancer12 recruiting
Acute myeloid leukaemia6 recruiting
Obesity6 recruiting
Ovarian cancer6 recruiting
Bladder cancer5 recruiting
Colorectal cancer5 recruiting
Melanoma5 recruiting
Multiple myeloma5 recruiting
Kidney cancer4 recruiting
Prostate cancer4 recruiting
Cervical cancer3 recruiting
Childhood cancers3 recruiting
Chronic lymphocytic leukaemia3 recruiting
Crohn's disease3 recruiting
Endometriosis3 recruiting
Fatty liver disease (MASLD/MASH)3 recruiting
Follicular lymphoma3 recruiting
Metastatic breast cancer3 recruiting
Myeloproliferative neoplasms3 recruiting
Ulcerative colitis3 recruiting
Amyloidosis2 recruiting
Chronic kidney disease2 recruiting
Diffuse large B-cell lymphoma2 recruiting
Endometrial cancer2 recruiting
High blood pressure2 recruiting
Myelodysplastic syndromes2 recruiting
Pancreatic cancer2 recruiting
Alzheimer disease1 recruiting
Ankylosing spondylitis1 recruiting
Asthma1 recruiting
Chronic myeloid leukaemia1 recruiting
Cystic fibrosis1 recruiting
Cytomegalovirus infection1 recruiting
Gastric and oesophageal cancer1 recruiting
Glioblastoma1 recruiting
Head and neck cancer1 recruiting
Heart failure1 recruiting
Hodgkin lymphoma1 recruiting
Liver and biliary tract cancer1 recruiting
Lupus (SLE)1 recruiting
Mantle cell lymphoma1 recruiting
Sarcoma1 recruiting
Systemic sclerosis (scleroderma)1 recruiting
Type 2 diabetes1 recruiting

Closed trials

Completed
Performances and Safety of MuCopilot, a Digital Tool for the Unsupervised Objective Assessment of Cystic Fibrosis
NCT06147778· Ad scientiam· Source
Completed
A safety study of PF-08046044/SGN-35C in adults with advanced cancers
NCT06254495· Phase 1· Seagen Inc.· Source
Completed
A Two-Part Study to Assess the Effectiveness, Safety, and Blood Levels of Repeat Doses of Inhaled ETD001 in People with Cystic Fibrosis
2023-504092-25-00· Phase 2· Enterprise Therapeutics Limited· Source
Completed
A Phase 1/2, Open-Label, Multicenter Trial Investigating the Safety, Tolerability, and Preliminary Antineoplastic Activity of IPH6501 in Patients with Relapsed and/or Refractory CD20-expressing Non-Hodgkin Lymphoma
NCT06088654· Phase 1/2· Innate Pharma· Source
Completed
Assessing Refractoriness and Infectious Survival Events in AML
NCT06709235· Hospices Civils de Lyon· Source
Completed
A Study to Evaluate the Efficacy, and Safety Study of Ruxolitinib Cream in Adults With Moderate Atopic Dermatitis
NCT06238817· Phase 3· Incyte Corporation· Source
Active, not recruiting
A Study to Learn About the Study Medicine Called PF-07220060 in Combination With Fulvestrant in People With HR-positive, HER2-negative Advanced or Metastatic Breast Cancer Who Progressed After a Prior Line of Treatment
NCT06105632· Phase 2· Pfizer· Source
Completed
A Dose Escalation and Cohort Expansion Study of KB-0742 in Participants With Relapsed or Refractory Solid Tumors or Non-Hodgkin Lymphoma.
NCT04718675· Phase 1· Kronos Bio Inc.· Source
Completed
Randomized, non-comparative, open-label early phase Ib study with OBT076 or OBT076 followed by Balstilimab in patients with Adenoid Cystic Carninoma of the Head and Neck
2023-503270-20-00· Phase 1· Groupe Oncologie Radiotherapie Tete Cou· Source
Completed
Study of DF6215 in Patients With Advanced Solid Tumors
NCT06108479· Phase 1· Dragonfly Therapeutics· Source
Recruiting
A basket study to investigate the efficacy and safety of SKB264 in combination with pembrolizumab in subjects with solid tumors
NCT05642780· Phase 2· Sichuan Kelun-Biotech Biopharmaceutical Co. Ltd.· Source
Terminated
Study of ART0380 in Patients With Biologically Selected Solid Tumors
NCT05798611· Phase 2· Artios Pharma Ltd· Source
Completed
A 32-week Trial to Evaluate the Efficacy and Safety of Tralokinumab in Subjects With Moderate-to-severe Atopic Hand Eczema Who Are Candidates for Systemic Therapy
NCT05958407· Phase 3· LEO Pharma· Source
Completed
Clinical trial of MK-7648A in adults and children with skin cancer
NCT05665595· Phase 3· Merck Sharp & Dohme LLC· Source
Completed
External Validation of Clinical Prediction Tools for Estimating Salt and Potassium Intake in Nephrology Patients.
NCT05783960· Hospices Civils de Lyon· Source
Completed
A Clinical Study of Efinopegdutide in Participants With Precirrhotic Nonalcoholic Steatohepatitis (NASH) (MK-6024-013)
NCT05877547· Phase 2· Merck Sharp & Dohme LLC· Source
Active, not recruiting
A Study of Efficacy and Safety of Pembrolizumab Plus Enfortumab Vedotin (EV) +/- Investigational Agents in First-Line Metastatic Urothelial Carcinoma (mUC) (MK-3475-04B/KEYMAKER-U04)
NCT05845814· Phase 1/2· Merck Sharp & Dohme LLC· Source
Active, not recruiting
A Study Evaluating the Effect of Filgotinib in Participants With Active Axial Spondyloarthritis
NCT05785611· Phase 3· Alfasigma S.p.A.· Source
Completed
Evaluation of an Automated System to Culture Metastatic Patient Circulating Tumor Cells in Embryonated Chicken Eggs (in Ovo Culture)
NCT05472532· Hospices Civils de Lyon· Source
Completed
Phase 2b Study of GSK4532990 in Adults With NASH
NCT05583344· Phase 2· GlaxoSmithKline· Source
Completed
A Study to Evaluate Adverse Events and Change in Disease Activity Comparing Oral Upadacitinib to Subcutaneous Dupilumab in Adolescent and Adult Participants With Moderate to Severe Atopic Dermatitis
NCT05601882· Phase 3· AbbVie· Source
Active, not recruiting
Study to Evaluate Elexacaftor/Tezacaftor/Ivacaftor (ELX/TEZ/IVA) Long-term Safety and Efficacy in Subjects Without F508del
NCT05331183· Phase 3· Vertex Pharmaceuticals Incorporated· Source
Completed
A Study to Evaluate MORF-057 in Adults With Moderately to Severely Active UC
NCT05611671· Phase 2· Morphic Therapeutic, Inc. (A Wholly Owned Subsidiary of Eli Lilly and Company)· Source
Withdrawn
A Platform Study of Novel Immunotherapy Products in Participants With Previously Treated Unresectable or Metastatic Cutaneous Melanoma
NCT05572463· Phase 1/2· Innovent Biologics (Suzhou) Co. Ltd.· Source
Terminated
Niraparib as First Line Therapy With Metastatic Homologous Repair-deficient Pancreatic Cancer
NCT05442749· Phase 2· Centre Leon Berard· Source
Completed
Assessment of Tobacco Smoking and Alcohol Drinking and Treatment Outcomes Among Patients With Lung or Head and Neck Cancer
NCT05523583· Hospices Civils de Lyon· Source
Completed
Staphylococcus Aureus in Atopic Dermatitis Immunopathology
NCT04715087· Hospices Civils de Lyon· Source
Terminated
A Study Evaluating Bemarituzumab in Solid Tumors With Fibroblast Growth Factor Receptor 2b (FGFR2b) Overexpression
NCT05325866· Phase 1/2· Amgen· Source
Completed
Study to Evaluate Efficacy, Safety, and Tolerability of RGH-706 in Prader-Willi Syndrome
NCT05322096· Phase 2· Gedeon Richter Plc.· Source
Completed
Effects of Triptorelin When Given Every 6-months Under the Skin to Adult Males With Cancer in the Prostate
NCT05458856· Phase 3· Ipsen· Source
Terminated
Study of Magrolimab Versus Placebo in Combination With Venetoclax and Azacitidine in Participants With Acute Myeloid Leukemia
NCT05079230· Phase 3· Gilead Sciences· Source
Completed
Tamibarotene/Venetoclax/Azacitidine in Previously Untreated Patients Selected for RARA-positive AML (SELECT-AML-1)
NCT04905407· Phase 2· Syros Pharmaceuticals Inc.· Source
Terminated
Study of Posoleucel (ALVR105,Viralym-M) for Multi-Virus Prevention in Patients Post-Allogeneic Hematopoietic Cell Transplant
NCT05305040· Phase 2/3· AlloVir· Source
Active, not recruiting
A Study of Daratumumab-Based Therapies in Participants With Amyloid Light Chain (AL) Amyloidosis
NCT05250973· Phase 2· Janssen Research & Development, LLC· Source
Completed
Adjuvant Immunotherapy with Nivolumab + Relatlimab Fixed-dose Combination versus Nivolumab Monotherapy after Complete Resection of Stage III-IV Melanoma
NCT05002569· Phase 3· Bristol Myers Squibb International Corporation· Source
Terminated
The Efficacy and Safety of Cobitolimod in Participants With Moderate to Severe Active Left-Sided Ulcerative Colitis
NCT04985968· Phase 3· InDex Pharmaceuticals· Source
Completed
Intratumoral Injection of LTX-315 in Combination With Pembrolizumab in Advanced Melanoma
NCT04796194· Phase 2· Lytix Biopharma AS· Source
Completed
A Study of VX-121 Combination Therapy in Participants With Cystic Fibrosis (CF) Who Are Homozygous for F508del, Heterozygous for F508del and a Gating (F/G) or Residual Function (F/RF) Mutation, or Have At Least 1 Other Triple Combination Responsive (TCR) CFTR Mutation and No F508del Mutation
NCT05076149· Phase 3· Vertex Pharmaceuticals Incorporated· Source
Terminated
A Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Healthy Participants 16 to 40 Years of Age
NCT05085366· Phase 3· ModernaTX, Inc.· Source
Completed
Study of Oral LOXO-338 in Patients With Advanced Blood Cancers
NCT05024045· Phase 1· Eli Lilly and Company· Source
Completed
Multicenter Retrospective Observatory of Patients With Acute Myeloid Leukemia to Core Binding Factor
NCT05070208· Acute Leukemia French Association· Source
Completed
A Study Evaluating the Safety, Efficacy and Pharmacokinetics of Venetoclax in Combination With Polatuzumab Vedotin Plus Rituximab (R) and Cyclophosphamide, Doxorubicin, Prednisone (CHP) in Participants With Untreated BCL-2 Immunohistochemistry (IHC)-Positive Diffuse Large B-Cell Lymphoma (DLBCL)
2023-507497-40-00· Phase 1· F. Hoffmann-La Roche AG· Source
Terminated
An Open-Label Phase 2 Trial of Nanatinostat Plus Valganciclovir in Patients With EBV+ Relapsed/Refractory Lymphomas
NCT05011058· Phase 2· Viracta Therapeutics, Inc.· Source
Completed
A Phase 3, Randomized, Double-Blind Study of Ociperlimab, an Anti-TIGIT Antibody, in Combination With Tislelizumab Compared to Pembrolizumab in Patients With Previously Untreated, PD-L1-Selected, and Locally Advanced, Unresectable, or Metastatic Non-Small Cell Lung Cancer
NCT04746924· Phase 3· Beigene Ltd.· Source
Terminated
NIRAPK : Study of the Relationship(s) Between Clinical, Biological and Pharmacokinetic Metrics and Toxicities When Niraparib is Used as Maintenance Treatment for Ovarian Cancer Patients.
NCT04861181· Phase 4· Hospices Civils de Lyon· Source
Completed
Substudy 02D: Safety and Efficacy of Pembrolizumab in Combination With Investigational Agents or Pembrolizumab Alone in Participants With Melanoma Brain Metastasis (MK-3475-02D/KEYMAKER-U02)
NCT04700072· Phase 1/2· Merck Sharp & Dohme LLC· Source
Completed
Study of Brexucabtagene Autoleucel (KTE-X19) in Participants With Relapsed/Refractory Mantle Cell Lymphoma (Cohort 3)
NCT04880434· Phase 2· Kite, A Gilead Company· Source
Completed
Multicentric Prospective Study to Screen Inborn Errors of Metabolism in Non-immune Hydrops (NIH) Fetalis by Massively Parallel Sequencing
NCT04308603· Hospices Civils de Lyon· Source
Completed
Interest of Tumor Replicates in Avian Embryo to Model Therapeutic Effects of BRAFi/MEKi in BRAF Mutated Melanoma
NCT04039672· Hospices Civils de Lyon· Source
Terminated
HC-1119 Versus Enzalutamide in Metastatic Castration-Resistant Prostate Cancer (mCRPC)
NCT03850795· Phase 3· Hinova Pharmaceuticals USA, Inc.· Source

Showing 50 of 125.

Registry name variants (100)

Trial registries list this institution under these names. Each row is one registry entry: its address and the trials registered under it.

Centre Hospitalier Lyon-Sud
Pierre-Bénite, Auvergne-Rhône-Alpes 69495
202 trials
Hopital Lyon Sud
Pierre-Bénite, 69310
23 trials
Centre Hospitalier Lyon Sud
Lyon, 69310
13 trials
HCL - Hôpital Lyon Sud
Lyon, France 69495
4 trials
Hopital Lyon Sud
Lyon, 69003
4 trials
Centre Hospitalier Lyon Sud
Pierre Benite Cedex, 69495
3 trials
- 2022-501554-11-00FILOCLL015 - GLORIFY - A phase 2 study evaluating the bispecific CD3xCD20 antibody GLOfitamab in combination with rituximab or obinutuzumab plus cyclophosphamide, doxorubicin, vincristine and prednisone (CHOP) in patients with RIchter syndrome as Frontline therapY
- NCT05785611A Study Evaluating the Effect of Filgotinib in Participants With Active Axial Spondyloarthritis
- NCT03142334Safety and Efficacy Study of Pembrolizumab (MK-3475) as Monotherapy in the Adjuvant Treatment of Renal Cell Carcinoma Post Nephrectomy (MK-3475-564/KEYNOTE-564)
Centre Hospitalier Lyon-Sud, CHLS
Pierre-Bénite, 69495
2 trials
- NCT07218146A Study of ZL-1310 Versus Investigator's Choice of Therapy in Participants With Relapsed Small Cell Lung Cancer (DLLEVATE)
- NCT05079230Study of Magrolimab Versus Placebo in Combination With Venetoclax and Azacitidine in Participants With Acute Myeloid Leukemia
Centre Hospitalier Lyon Sud - Department of Medical Oncology
Pierre-Bénite
2 trials
- NCT05472532Evaluation of an Automated System to Culture Metastatic Patient Circulating Tumor Cells in Embryonated Chicken Eggs (in Ovo Culture)
- NCT04605146Impact of Telemonitoring for the Management of Side Effects in Patients with Melanoma, Lung or Renal Cancer, Treated with Immunotherapy Combination of Nivolumab and Ipilimumab or Adjuvant Nivolumab Monotherapy
  Contact: Denis MAILLET, MD
Hôpital Lyon Sud - HCL
Pierre-Bénite, 69495
2 trials
- NCT06356740Efficacy and Tolerance of Abacavir/Lamivudine Treatment in Patients With Systemic Lupus Erythematosus
  Contact: Mael Richard, MD
- NCT04469686Phase 3 Study to Evaluate the Safety and Efficacy of Hydrocortisone Acetate Suppositories
Lyon Sud Hospital
Pierre-Bénite, 69310
2 trials
- NCT05835973Evaluation of Sleep Changes in Inflammatory Bowel Diseases (IBD) Patients.
  Contact: Gilles BOSCHETTi, MD,PhD
- NCT05091190Immunotherapy Clearance and Phenotype of Circulating Tumor Cells in Lung and Head and Neck Cancers
" Centre de dépistage mobile " - Hôpital Lyon Sud
Pierre-Bénite, 69310
1 trial
- NCT07015151Mobile Lung Cancer Screening
  Contact: Sébastien COURAUD, Pr
Centre de Recherche en Nutrition Humaine Rhône-Alpes, Centre Hospitalier Lyon Sud
Pierre-Bénite, 69495
1 trial
- NCT07638111SENSILINS: Impact of Cephalic Phase Insulin Release Induced by an Environmental Food Odor Stimulus on Glucose Homeostasis According to Insulin Sensitivity Level
  Contact: Anne Laure CASTELL, MD
Centre Hospitalier Lyon Sud
Oullins, 69495
1 trial
- NCT07837986Investigation of Type I Interferon Excess in Patients With Systemic Autoimmune Diseases and Genetic Type I Interferonopathies
  Contact: Maël RICHARD, MD
Centre Hospitalier Lyon Sud
Pierre-Bnite, Rhone 69310
1 trial
- NCT04434092A Study Evaluating the Efficacy and Safety of Crovalimab Versus Eculizumab in Participants With Paroxysmal Nocturnal Hemoglobinuria (PNH) Not Previously Treated With Complement Inhibitors
Centre Hospitalier Lyon Sud (Adultes)
Lyon, 69495
1 trial
- NCT06147778Performances and Safety of MuCopilot, a Digital Tool for the Unsupervised Objective Assessment of Cystic Fibrosis
Centre Hospitalier Lyon Sud, Endocrinologie, Diabète et nutrition
Pierre-Bénite, France 69495
1 trial
- NCT06868992Study of the Link Between MASH ( Metabolic Dysfunction-Associated Steatohepatitis) and MAMs (Mitochondria-Associated Membranes ) Alteration in Patients Undergoing Bariatric Surgery - MAMBA
  Contact: Cyrielle CAUSSY, Pr
Centre Hospitalier Lyon Sud - Hématologie
Pierre-Bénite, 69495
1 trial
- NCT04703192Valemetostat Tosylate (DS-3201b), an Enhancer of Zeste Homolog (EZH) 1/2 Dual Inhibitor, for Relapsed/Refractory Peripheral T-Cell Lymphoma (VALENTINE-PTCL01)
Centre Hospitalier Lyon Sud, Lyon
Lyon
1 trial
- NCT05580861Sulfasalazine in AML Treated by Intensive Chemotherapy: Elderly Patients-first Line Treatment
  Contact: Mael Heiblig, Dr
Centre Hospitalier Lyon-Sud, Service d'Hematologie
Pierre-Bénite, 69495
1 trial
- NCT02924402Study to Evaluate Safety and Tolerability of XmAb13676 (Plamotamab) in Patients With CD20-expressing Hematologic Malignancies
Centre Hospitalier Lyon Sud - Service oncologie medicale
Pierre-Bénite, Auvergne-Rhône-Alpes 69310
1 trial
- NCT06760819A Study to Learn More About How Well Treatment With Sevabertinib (BAY 2927088) Tablets Works and How Safe it is in Participants Who Have a Solid Tumor With Mutations of the Human Epidermal Growth Factor Receptor 2 (HER2)
Centre Hospitalier Lyon Sud (Site 0354)
Pierre-Bénite, Rhone 69310
1 trial
- NCT04195750A Study of Belzutifan (MK-6482) Versus Everolimus in Participants With Advanced Renal Cell Carcinoma (MK-6482-005)
centre hospitalier lyon sud (Site 0707)
Pierre-Bénite, Rhone 69310
1 trial
- NCT06052059A Study to Evaluate Efficacy and Safety of Tulisokibart (MK-7240) in Participants With Moderately to Severely Active Ulcerative Colitis (MK-7240-001)
Centre Hospitalier Lyon-Sud (Site 0804)
Pierre-Bénite, Auvergne-Rhône-Alpes 69495
1 trial
- NCT04728893Efficacy and Safety of Nemtabrutinib (MK-1026) in Participants With Hematologic Malignancies (MK-1026-003)
  Contact: Study Coordinator
Centres Hospitalier Lyon Sud, Service d'Endocrinologie-Diabète-Nutrition
Pierre-Bénite, 69310
1 trial
- NCT05783466Dairy Lipids and Cardiometabolic Risk
  Contact: Emmanuel DISSE, Pr
HCL - Hôpital Lyon Sud
Pierre-Bénite
1 trial
- NCT07141017Initial Standardized Global Review in Axial Spondyloarthritis
  Contact: Cyrille Confavreux
HCL - Hôpital Lyon Sud /ID# 151146
Pierre-Bénite, Auvergne-Rhône-Alpes 69495
1 trial
- NCT02738125Assessing Effectiveness of Adalimumab for Treating Ulcerative Colitis in Real Life Conditions
HCL - Hôpital Lyon Sud /ID# 151505
Pierre-Bénite, Auvergne-Rhône-Alpes 69495
1 trial
- NCT02738125Assessing Effectiveness of Adalimumab for Treating Ulcerative Colitis in Real Life Conditions
HCL - Hôpital Lyon Sud /ID# 165859
Pierre-Bénite, Auvergne-Rhône-Alpes 69495
1 trial
- NCT02738125Assessing Effectiveness of Adalimumab for Treating Ulcerative Colitis in Real Life Conditions
HCL - Hopital Lyon Sud /ID# 222447
Pierre-Bénite, Rhone 69495
1 trial
- NCT04497597A Study of Oral Upadacitinib Tablets to Assess Treatment Patterns, Achievement of Treatment Targets and Maintenance of Response in Adult Participants With Moderate to Severe Rheumatoid Arthritis
HCL - Hopital Lyon Sud /ID# 222695
Pierre-Bénite, Rhone 69495
1 trial
- NCT04468984Study of Oral Navitoclax Tablet in Combination With Oral Ruxolitinib Tablet Versus Best Available Therapy to Assess Change in Spleen Volume in Adult Participants With Relapsed/Refractory Myelofibrosis
HCL - Hopital Lyon Sud /ID# 222913
Pierre-Bénite, Rhone 69495
1 trial
- NCT04472598Study of Oral Navitoclax Tablet In Combination With Oral Ruxolitinib Tablet When Compared With Oral Ruxolitinib Tablet To Assess Change In Spleen Volume In Adult Participants With Myelofibrosis
HCL - Hopital Lyon Sud /ID# 248864
Pierre-Bénite, Rhone 69495
1 trial
- NCT05669794An Observational Study to Assess Change in Disease Activity and Use of Upadacitinib Tablets in Adolescent and Adult Participants With Moderate to Severe Atopic Dermatitis in Real World
HCL - Hopital Lyon Sud /ID# 251343
Pierre-Bénite, Rhone 69495
1 trial
- NCT05601882A Study to Evaluate Adverse Events and Change in Disease Activity Comparing Oral Upadacitinib to Subcutaneous Dupilumab in Adolescent and Adult Participants With Moderate to Severe Atopic Dermatitis
HCL - Hopital Lyon Sud /ID# 252093
Pierre-Bénite, Rhone 69495
1 trial
- NCT05494606An Observational Study to Assess Change in Disease Activity and Adverse Events of Upadacitinib in Adult Participants With Moderate to Severe Ulcerative Colitis (UC) in Real-World Practice
HCL - Hopital Lyon Sud /ID# 253104
Pierre-Bénite, Rhone 69495
1 trial
- NCT05841537An Observational Study to Assess Change in Disease Activity and Adverse Events In Adult Participants With Moderate to Severe Active Crohn's Disease (CD)
HCL - Hopital Lyon Sud /ID# 272178
Pierre-Bénite, Rhone 69495
1 trial
- NCT06682988A Study to Assess Adverse Events and Change in Disease Activity in Participants With Platinum-Resistant Advanced High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers With High Folate Receptor-Alpha Expression Treated With Intravenously (IV) Infused Mirvetuximab Soravtansine
Hôpital Lyon Sud
Oullins
1 trial
- NCT07437326Food-related Quality of Life in Patients With Cancer
  Contact: Benoit YOU, Pr
Hôpital Lyon Sud
Oullins-Pierre-Bénite, 69495
1 trial
- NCT06781099Feasibility Trial of Extracorporeal Iron Purification in Patients With Myelodysplastic Syndrome or Myelofibrosis
  Contact: Auguste DARGENT, MD, PhD
Hôpital Lyon Sud - Department of Dermatology, HCL-Cancer Institute
Pierre-Bénite
1 trial
- NCT04605146Impact of Telemonitoring for the Management of Side Effects in Patients with Melanoma, Lung or Renal Cancer, Treated with Immunotherapy Combination of Nivolumab and Ipilimumab or Adjuvant Nivolumab Monotherapy
  Contact: Stéphane DALLE, MD
Hôpital Lyon Sud - Department of pneumology,Thoracic oncology
Pierre-Bénite
1 trial
- NCT04605146Impact of Telemonitoring for the Management of Side Effects in Patients with Melanoma, Lung or Renal Cancer, Treated with Immunotherapy Combination of Nivolumab and Ipilimumab or Adjuvant Nivolumab Monotherapy
  Contact: Pierre Jean SOUQUET, MD
Hôpital Lyon sud, Endocrinology Diabetes Nutrition department
Pierre-Bénite, 69310
1 trial
- NCT07268508Impact of a Pro-diversity Gut Microbiota Diet After a Bariatric Surgery on Gut Microbiota, Eating Behaviour and Sensory Function
  Contact: Berenice SEGRESTIN
Hopital Lyon Sud - Hcl
Lyon, 69495
1 trial
- NCT07317037ActiTENS Mini (Transcutaneous Electrical Stimulation) in Women With Chronic Pain From Pelvic Endometriosis
  Contact: BOLZE PIERRE-ADRIEN
Hôpital Lyon sud, Institut de Cancérologie des Hospices Civils de Lyon
Pierre-Bénite, 69495
1 trial
- NCT04861181NIRAPK : Study of the Relationship(s) Between Clinical, Biological and Pharmacokinetic Metrics and Toxicities When Niraparib is Used as Maintenance Treatment for Ovarian Cancer Patients.
Hôpital Lyon Sud, Pneumologie
Pierre-Bénite, 69310
1 trial
- NCT05523583Assessment of Tobacco Smoking and Alcohol Drinking and Treatment Outcomes Among Patients With Lung or Head and Neck Cancer
Hôpital Lyon Sud/ service de Radiothérapie Oncologie
Lyon, 69495
1 trial
- NCT06041555MRI Guided Radiotherapy and Radiobiological Data: the ISRAR Database (Irm Sequences for Radiobiological Adaptative Radiotherapy)
  Contact: Olivier CHAPET, MD
Hospices Civil De Lyon Nord - Centre Hospitalier Lyon Sud - Dermatologie
Lyon, 69002
1 trial
- NCT05572463A Platform Study of Novel Immunotherapy Products in Participants With Previously Treated Unresectable or Metastatic Cutaneous Melanoma
Hospices Civiles de Lyon - Hôpital Lyon Sud
Pierre-Bénite
1 trial
- NCT04913285A Study to Evaluate KIN-2787 in Participants With BRAF and/or NRAS Mutation Positive Solid Tumors
  Contact: Stephane Dalle, MD
Lyon Hôpital Sud
Lyon
1 trial
- NCT06356831National Registry of Surgical Treatment and Percutaneous Cryoablation of Parietal Endometriosis
  Contact: Alexandre GALAN, Dr
Lyon Sud Hospital - Hepatology and Gastroenterology Department
Lyon, 69310
1 trial
- NCT07260617Association Between Composition of the Gut Microbiota and Nutritional Status in Digestive Oncology
  Contact: Gilles Boschetti, Dr
Service de Dermatologie, Centre hospitalier Lyon Sud, HCL
Pierre-Bénite, 69495
1 trial
- NCT04039672Interest of Tumor Replicates in Avian Embryo to Model Therapeutic Effects of BRAFi/MEKi in BRAF Mutated Melanoma
Service de Gériatrie, Centre Hospitalier Lyon Sud, 165 chemin du Grand Revoyet
Pierre-Bénite, 69495
1 trial
- NCT04284969PROADAPT-ovary/EWOC-2
  Contact: Claire FALANDRY, PR
Service d'Endocrinologie, Diabète et Nutrition - Centre Hospitalier Lyon Sud - HCL
Pierre-Bénite, 69495
1 trial
- NCT03610256Single-anastomosis Duodeno Ileal Bypass (SADI) Versus Roux-en-Y Gastric Bypass
Service de Pneumologie " Centre de dépistage non mobile " - Hôpital Lyon Sud
Pierre-Bénite, 69310
1 trial
- NCT07015151Mobile Lung Cancer Screening
  Contact: COURAUD Sébastien, Pr
Service d'hématologie, Hôpital Lyon Sud
Pierre-Bénite, Lyon 69495
1 trial
- NCT06421025Blood Viscosity in Polycythemia Patients
  Contact: Mael HEIBLIG, MD,PhD
Service d'Hépato-Gastroentérologie, Centre Hospitalier Lyon-Sud, HCL
Pierre-Bénite, 69495
1 trial
- NCT03915262Exocrine Pancreatic Insufficiency's Prevalence in Active Crohn's Disease
  Contact: Gilles BOSCHETTI, MD
Service MB1 - Hôpital Lyon Sud - HCL
Lyon, Pierre-Bénite 69495
1 trial
- NCT05942885Hypnosis: a Path to Appeasement
  Contact: Thomas Bert
Service Oncologie Médicale, Hôpital Lyon Sud
Pierre-Bénite, 69495
1 trial
- NCT06572735Study on the Relative Dose Intensity of PARP Inhibitors in Real-life on a Population of Patients Over 70 Years With Advanced Ovarian Cancer
  Contact: Nathalie BONNIN, MD
Centre Hospitalier Lyon Sud
Pierre BĂŠnite, 69495
Centre Hospitalier Lyon Sud
Saint-Genis-Laval
Centre Hospitalier Lyon Sud /ID# 159705
Pierre-Bénite, Rhone 69495
centre hospitalier lyon sud-Service de dermatologie (Site 1202)
Pierre-Bénite, Rhone 69310
Centre Hospitalier Lyon Sud - service d'oncologie medicale
Pierre-Bénite
centre hospitalier lyon sud;Service Hématologie
Pierre-Bénite, Rhône 69310
centre hospitalier lyon sud-Service Hématologie (Site 0702)
Pierre-Bénite, Rhone 69310
centre hospitalier lyon sud-Service Hématologie (Site 1501)
Pierre-Bénite, Rhone 69310
centre hospitalier lyon sud (Site 0343)
Pierre-Bénite, Rhone 69310
centre hospitalier lyon sud (Site 0406)
Pierre-Bénite, Rhone 69310
Centre Hospitalier Lyon Sud (Site 0413)
Pierre-Bénite, Rhone 69310
centre hospitalier lyon sud (Site 0497)
Pierre-Bénite, Rhone 69310
centre hospitalier lyon sud (Site 0716)
Pierre-Bénite, Rhone 69310
centre hospitalier lyon sud (Site 1003)
Pierre-Bénite, Rhone 69310
Centre Hospitalier Lyon Sud (Site 1102)
Pierre-Bénite, Rhone 69495
Centre Hospitalier Lyon Sud (Site 2064)
Pierre-Bénite, Rhone 69310
Centre Hospitalier Lyon Sud (Site 3102)
Pierre-Bénite, Rhone 69495
centre hospitalier lyon sud (Site 3606)
Pierre-Bénite, Rhone 69310
centre hospitalier lyon sud (Site 3901)
Pierre-Bénite, Rhone 69310
Centre Hospitalier Lyon Sud (Site 4102)
Pierre-Bénite, Rhone 69495
Centre Hospitalier Lyon Sud (Site 4606)
Pierre-Bénite, Auvergne-Rhône-Alpes 69310
Ch - Hôpital Lyon Sud
Pierre-Bénite, 69310
HCL - Hopital Lyon Sud /ID# 152540
Pierre-Bénite, Rhone 69495
HCL - Hopital Lyon Sud /ID# 162560
Pierre-Bénite, Rhone 69495
HCL - Hopital Lyon Sud /ID# 171030
Pierre-Bénite, Rhone 69495
HCL - Hopital Lyon Sud /ID# 200097
Pierre-Bénite, Rhone 69495
HCL - Hôpital Lyon Sud /ID# 201529
Pierre-Bénite, Auvergne-Rhône-Alpes 69495
HCL - Hopital Lyon Sud /ID# 213508
Pierre-Bénite, Rhone 69495
HCL - Hopital Lyon Sud /ID# 227086
Pierre-Bénite, Rhone 69495
HCL - Hopital Lyon Sud /ID# 231449
Pierre-Bénite, Rhone 69495
HCL - Hopital Lyon Sud /ID# 242349
Pierre-Bénite, Rhone 69495
HCL - Hopital Lyon Sud /ID# 251223
Pierre-Bénite, Rhone 69495
HCL - Hopital Lyon Sud /ID# 260508
Pierre-Bénite, Rhone 69495
HCL - Hopital Lyon Sud /ID# 282145
Pierre-Bénite, Rhone 69495
Hôpital Lyon Sud - Chirurgie Digestive et Oncologique
Pierre-Bénite, 69495
Hôpital Lyon Sud - Chirurgie Gynécologique et oncologique-obstétrique
Pierre-Bénite
Hôpital Lyon Sud - Oncologie Médicale
Pierre-Bénite
Hôpital Lyon Sud - Pulmonology
Pierre-Bénite
Hospital Lyon Sud
Pierre-Bénite
Hospital Lyon-Sud (HCL)
Pierre-Bénite, 69310
Lyon Sud Hospital Center
Pierre-Bénite
Oncologie Médicale, Centre Hospitalier Lyon Sud, HCL
Pierre-Bénite, 69310
Service de médecine interne - Hôpital Lyon Sud
Lyon, 69004

Conditions

Diseases this institution publishes on or runs trials for.

Acute myeloid leukaemia28 works · 22 trials
Hodgkin lymphoma16 works · 9 trials
Follicular lymphoma14 works · 11 trials
Myelodysplastic syndromes8 works · 9 trials
Chronic myeloid leukaemia6 works · 6 trials
Mesothelioma5 works · 1 trial

Institution data: ROR 023xgd207 (CC0-1.0)Updated 10 Nov 2026

Report an error